Looks like there might be some good news on the DARRT 2 trial, The trial Changes (Side-by-Side) for Study: NCT04957290 have been updated on the FDA website on January 26, 2023.
Looks like Noxopharm has been approved to proceed with up to 70 patients down from 100 which is positive on saving money on the trial and possibly a positive outcome on the patients already treated that they can reach an outcome with less patients.
Original announcement: Enrollment:100 [Anticipated] Changed to: 70 [Anticipated]
Happy to hear others thoughts on this ?
Ann: December 2022 Quarterly Activities Report and Appendix 4C, page-35
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.3¢ |
Change
-0.008(6.82%) |
Mkt cap ! $29.95M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.0¢ | $5.512K | 52.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 77561 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 173913 | 1 |
View Market Depth
| Last trade - 15.59pm 27/08/2024 (20 minute delay) ? |
| NOX (ASX) Chart |